Navigation Links
Arpida to Discuss Strategy With Shareholders

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- Arpida Ltd. (SIX: ARPN) will today discuss potential strategic scenarios with its shareholders during the Annual General Meeting (AGM) which starts at 10am CET in Reinach, Switzerland.

After the negative FDA opinion regarding intravenous iclaprim, Arpida has initiated a thorough analysis with the aim to design a roadmap towards approval. The company was supported by international experts in this field.

As Arpida lacks both the time and the money to complete this path, a search for funding or other strategic options took place in parallel. The search for fresh funds did not yield any results as access to credit lines or equity funding is not available.

During the last months, Arpida, supported by external advisors, has explored all other strategic scenarios, including 'reverse mergers', takeovers, asset sales as well as liquidation as a last resort.

Board and Management currently pursue business development contacts with 72 companies, both inside Switzerland and abroad. Of these, Arpida focuses on 5 that have advanced into negotiations which are currently ongoing. At today's meeting no vote is planned on this item, as no concrete proposal is available at this time. If and when a major strategic proposal is made, shareholders will obviously be duly involved.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Arpida contacts:

    Dr Jurgen Raths, President and CEO,Tel: +41-61-417-96-60;
    Harry Welten, MBA, CFO and Senior Vice President,Tel: +41-61-417-96-65;
    Paul Verbraeken, Head of Corporate Communications,Tel: +41-61-417-96-83.

SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Arpida to Restructure and Focus on Key Projects
3. Arpidas iclaprim MAA Accepted for Review by EMEA
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
8. Arpida Announces Conference Call on 17 April
9. Arpida Announces Agenda Items for Shareholders Meeting
10. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
11. Arpida Announces Full Year 2007 Financial Results
Post Your Comments:
(Date:10/13/2015)... and TORONTO , Oct. 13, 2015 ... announced that it has entered into a non-binding Letter of ... private Israeli company that has developed a proprietary cooling technology ... to varicoceles. the United States ... between the ages of 25 and 44 diagnosed as infertile.  ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr and Ed ... growing clinical data solutions business. , Jeff Parr has spent the past decade providing ... Avery Dennison, Thermo Fisher, and Ab Sciex to name a few. He is ...
(Date:10/13/2015)... ... ... Proove Biosciences, a commercial and research leader ... Medicine of the University of Southern California (USC) Pain Center to study ... Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one of ...
(Date:10/13/2015)... the United States , Canada ... 14% of all new cases of kidney cancer.   --> ... and Europe .  PRCC represents about 14% ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison ... ("AstraZeneca") have completed enrolment in a global Phase II study of ...
Breaking Biology Technology:
(Date:10/6/2015)... 2015 Track Group, Inc. (OTCQX: TRCK), a ... signed a contract with the Virginia Department of Corrections ... of sentences under the Department,s oversight. Derek ... contract with the Virginia DOC will expand our footprint ... our position as a trusted leader in offender electronic ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/30/2015)... 2015  The U.S. Court of Appeals for the ... in favor of Crossmatch ™, affirming the International ... Suprema and its U.S. partner Mentalix violated Section 337 ... that declares it unlawful to engage in "unfair practices" ... Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 patent. ...
Breaking Biology News(10 mins):